Logo image
Back
Angiopoietin‐like protein 2 and mortality in patients with heart failure—Results from an observational study
Journal article   Peer reviewed

Angiopoietin‐like protein 2 and mortality in patients with heart failure—Results from an observational study

Eva Maria Brandtner, Andreas Leiherer, Barbara Larcher, Kathrin Geiger, Christine Heinzle, Laura Schnetzer, Christoph H. Saely, Heinz Drexel and Axel Muendlein
European journal of clinical investigation, v 56(1), e70143
Jan 2026
DOI: https://doi.org/10.1111/eci.70143
PMID: 41181893
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

angiopoietin‐like protein 2 ANGPTL2 biomarker mortality prognosis Heart Failure
Background Heart failure is an advanced form of cardiovascular disease with a high mortality rate. Management of the condition is possible and blood‐based biomarkers could help identify the most vulnerable patients. There is mounting evidence of a link between angiopoietin‐like protein 2 (ANGPTL2), a secreted glycoprotein involved in inflammation and tissue remodelling, and heart failure. However, no prospective studies have examined whether ANGPTL2 predicts mortality in heart failure, which this study aims to address. Methods Mortality was prospectively recorded in a cohort of 303 patients with heart failure over a period of 5 years. Serum ANGPTL2 levels were determined at baseline by means of enzyme‐linked immunosorbent assay. Results At baseline, elevated ANGPTL2 levels were highly significantly associated with increased concentrations of total, LDL‐ and HDL‐cholesterol and with a lower prevalence of male sex, smoking history, cardiovascular disease and statin use. During the five‐year follow‐up period, 47% of all patients died. When patients were stratified into tertiles based on ANGPTL2 levels, those in the highest tertile exhibited a significantly increased risk of all‐cause mortality compared to those in the lowest tertile (hazard ratio = 1.88 [1.23–2.88]; p = .004). After adjustment for potential confounders, including NT‐proBNP, the association remained significant, with an adjusted hazard ratio of 1.91 [1.13–3.23]; p = .015. In addition, the inclusion of ANGPTL2 improved the predictive accuracy of a model based on traditional risk factors, as indicated by a significant 24.3% net reclassification improvement. Conclusion Circulating ANGPTL2 is a significant predictor of mortality in patients with heart failure. This study aimed to evaluate the association between circulating ANGPTL2 concentrations and all‐cause mortality in 303 patients with heart failure over a five‐year follow‐up period. Kaplan–Meier analysis demonstrated a significantly reduced survival probability with higher ANGPTL2 levels (log‐rank p = .007). In multivariable Cox regression analysis, the association between elevated ANGPTL2 and mortality remained independent after adjustment for conventional risk factors, including NT‐proBNP. In conclusion, circulating ANGPTL2 is a novel independent predictor of mortality in patients with heart failure.

Metrics

1 Record Views
1 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
International collaboration
Web of Science research areas
Medicine, Research & Experimental
Logo image